Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.72 |
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.72 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.72 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | DPP4 | P27487 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.72 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.72 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.72 |
| ▸ | GAPDH | P04406 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | STAT6 | P42226 | 1/20 | 0.72 |
| ▸ | PI4KA | P42356 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.72 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.72 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.72 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL2327105 | 1.00 | ADORA3 (0.72) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28241706 | 0.99 | ADORA3 (0.71) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL347374 | 0.97 | ADORA3 (0.71) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL29036082 | 0.97 | ADORA3 (0.71) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28057366 | 0.96 | ADORA1 (0.67) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL9419203 | 0.93 | ADORA1 (0.63) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28224468 | 0.93 | ADORA3 (0.63) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL27686613 | 0.93 | P2RY2 (0.65) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL27793299 | 0.90 | ADORA3 (0.71) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL18953147 | 0.90 | P2RY2 (0.62) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115666587-A | N4-hydroxycytidine and derivatives and related antiviral uses thereof | 埃默里大学 | 2023-01-31 | — | — | CN | claimed |
| CN-106929553-B | Method for synthesizing vidarabine by enzyme method | 上海鑫欣生物科技有限公司 | 2021-02-19 | — | — | CN | claimed |
| CN-112079883-A | Production process of vidarabine | 兰州欣立医药科技有限责任公司 | 2020-12-15 | — | — | CN | claimed |
| CN-108948189-A | Novel HA binding reagents | 威特拉公司 | 2018-12-07 | — | — | CN | claimed |
| CN-105979951-A | 4' -difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication | 里博科学有限责任公司 | 2016-09-28 | — | — | CN | claimed |
| CN-102770541-B | Comprise the oligonucleotide compound that non-nucleotide is outstanding | QUARK PHARMACEUTICALS, INC. (US) | 2016-03-09 | — | — | CN | claimed |
| CN-102770541-A | Oligonucleotide compounds comprising non-nucleotide overhangs | QUARK PHARMACEUTICALS INC | 2012-11-07 | — | — | CN | claimed |
| US-20230346831-A1 | METHODS FOR TREATING METASTATIC CANCER USING LOW DOSE CARBON MONOXIDE | CORNELL UNIVERSITY (US) | 2023-11-02 | — | — | US | disclosed |
| CN-115666587-A | N4-hydroxycytidine and derivatives and related antiviral uses thereof | 埃默里大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-114502548-A | Crystalline forms of a CD73 inhibitor | 伊莱利利公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114469958-A | Method for prophylactic treatment of viruses and pre-exposure prophylactic kit | 艾利安有限责任公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-106929553-B | Method for synthesizing vidarabine by enzyme method | 上海鑫欣生物科技有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-112079883-A | Production process of vidarabine | 兰州欣立医药科技有限责任公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-1128270-A | Synthetic method of arabinosyladenosine | GUANGDONG PROV INST OF MATERIA (CN) | 1996-08-07 | — | — | CN | disclosed |
| CN-1086543-A | Clones coding has the cDNA of people's graininess scavenger cell and eosinophie cellular growth active polypeptide | SCHERING BIOTECH CORP (US) | 1994-05-11 | — | — | CN | disclosed |
| CN-1020473-C | cDNA clones encoding polypeptides exhibiting human granulocyte macrophage and eosinophil growth factor activity | SCHERING BIOTECH CORP (US) | 1993-05-05 | — | — | CN | disclosed |
| CN-1068744-A | The medicament of Asialoglycoprotein-conjugated medicinal | LIVER RESEARCH FOUNDATION OF K (KR) | 1993-02-10 | — | — | CN | disclosed |
| CN-1013448-B | N6Process for producing-substituted deoxyriboadenosine analogues | WARNER LAMBERT CO (US) | 1991-08-07 | — | — | CN | disclosed |
| CN-85109132-A | Cloning of cDNA encoding Polypeptides having human granulocyte macrophage and eosinophil growth factor Activity | — | 1986-12-03 | — | — | CN | disclosed |
| CN-85108658-A | N 6The manufacture method that replaces ribodesose adenyhomotype thing | — | 1986-07-16 | — | — | CN | disclosed |